IL-13, or Interleukin-13, is a cytokine that plays a crucial role in various inflammatory and immune-mediated diseases. It is primarily associated with allergic asthma and atopic dermatitis, where it promotes airway hyperresponsiveness, mucus production, and inflammation. IL-13 inhibitors target the IL-13 signaling pathways to mitigate these disease manifestations, improving clinical outcomes. IL-13 inhibitors are also being explored for other indications, including eosinophilic esophagitis and nasal polyps, due to the involvement of IL-13 in these conditions. According to the World Health Organization (WHO), asthma affects approximately 334 million people worldwide, with Europe and the United States accounting for a significant burden. In Europe, asthma affects around 30 million people, resulting in substantial healthcare costs and productivity losses. The prevalence of atopic dermatitis is estimated to be around 1-3% in adults and up to 20% in children in Europe. In the United States, asthma affects around 25 million people, with an annual cost exceeding $56 billion. Atopic dermatitis affects approximately 7.3% of adults and 12.5% of children in the US, resulting in a significant economic burden.
The growth drivers of the IL-13 market include the increasing incidence and prevalence of allergic asthma and atopic dermatitis, advancements in biotechnology and the development of innovative IL-13 inhibitors, expanding target indications such as eosinophilic esophagitis and nasal polyps, and collaborations between pharmaceutical companies and research institutions accelerating drug development. Companies such as Arjil Pharma, GSK, Pfizer, Fortress, Novartis, Akesobio, Sanofi, Ionis, Menarini, Amgen, Roche, Cellabmed, J&J, Suzhou Maximum Bio-Tech, AstraZeneca, Shanghai Simnova Bio, Gilead cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Novartis is one such company that is currently conducting a clinical trial of the drug QAX576 for the treatment of Asthma.
Key Developments
- In June 2023, LEO Pharma launched Adbry for Atopic dermatitis (In adults) in Saudi Arabia.
- In April 2023, CHMP issued a positive opinion recommending the approval of tralokinumab single dose (300 mg) 2 ml pre-filled pen for the treatment of atopic dermatitis in the European Union.
Approved IL-13 molecules
- Dupixent (dupilumab)
- Adbry (tralokinumab-ldrm)
- Aerovant (pitrakinra)
IL-13 Pipeline Molecules
- Lebrikizumab (LY3650150)
- CM310
- Dectrekumab (QAX576)
- Cendakimab (CC-93538)
- Deuterated S-lisofylline (PCS499)
- Anrukinzumab (IMA-638)
- Eblasakimab (ASLAN004)
- AR100
- GSK679586
- IMA 026
- MB-101
- QBX-258
- Manfidokimab (AK120)
- Romilkimab (SAR156597)
- AIR645
- ICT-107
- SL-701
- AMG 317
- BITS7201A
- CLM-103
- CNTO 5825
- GSK2434735
- IL-13Rα2 UCAR-T cell therapy
- PF-07264660
- PF-07275315
- QAX-567
- R256
- SAR443765
- SC-CAR4BRAIN
- SNC109
- TmEGFR, IL13Rα2 01 CAR-T
- Abrezekimab (VR942)
- Hypochlorous acid (PR022)
Clinical Activity and Development of IL-13
In the IL-13 space, more than 15 companies are conducting more than 200 clinical trials in this category of drugs. For instance,
- In November 2022, Celgene Corporation completed a phase II trial of Cendakimab in atopic dematitis in Canada, China, the Czech Republic, Japan, Poland, and the USA
- In May 2023, Eli Lilly released efficacy and adverse events data from phase III advocate1, advocate2, and adhere trials of Lebrikizumab in atopic dermatitis.
|
Product Name |
Total Studies |
|
lebrikizumab (LY3650150) |
34 |
|
CM310 |
18 |
|
dectrekumab (QAX576) |
15 |
|
cendakimab (CC-93538) |
12 |
|
deuterated S-lisofylline (PCS499) |
6 |
|
anrukinzumab (IMA-638) |
5 |
|
eblasakimab (ASLAN004) |
4 |
|
AR100 |
3 |
|
GSK679586 |
3 |
|
IMA 026 |
3 |
|
MB-101 |
3 |
|
QBX-258 |
3 |
|
manfidokimab (AK120) |
3 |
|
romilkimab (SAR156597) |
3 |
|
AIR645 |
2 |
|
ICT-107 |
2 |
|
SL-701 |
2 |
|
AMG 317 |
1 |
|
BITS7201A |
1 |
|
CLM-103 |
1 |
Target Indication Analysis of IL-13
IL-13, or Interleukin-13, is a cytokine that plays a critical role in various inflammatory and immune-mediated diseases. It is primarily associated with allergic asthma and atopic dermatitis, where it promotes airway hyperresponsiveness, mucus production, and inflammation. Targeting IL-13 has emerged as a promising therapeutic strategy to mitigate these disease manifestations. IL-13 inhibitors, such as monoclonal antibodies, aim to block IL-13 signaling pathways, thus reducing airway inflammation and improving clinical outcomes. Additionally, IL-13 is implicated in other conditions like eosinophilic esophagitis and nasal polyps, expanding the potential target indications for IL-13 inhibitors in the treatment of diverse inflammatory disorders.
IL-13 Market Regional Analysis
IL-13 Market
The global IL-13 market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The IL-13 market in the United States has witnessed significant growth in recent years. With a high prevalence of allergic asthma and atopic dermatitis, the demand for IL-13 targeted therapies has been on the rise. The market is dominated by monoclonal antibody-based therapies, which have demonstrated efficacy in reducing inflammation and improving patient outcomes. The availability of advanced healthcare infrastructure, robust research and development activities, and favorable reimbursement policies further contribute to the market growth. However, the high cost of IL-13 inhibitors and the presence of alternative treatment options pose challenges to market expansion. everal factors drive the growth of the IL-13 market. Firstly, the increasing incidence and prevalence of allergic asthma and atopic dermatitis have created a substantial patient pool in need of effective treatments. Secondly, the growing understanding of the role of IL-13 in various inflammatory disorders, such as eosinophilic esophagitis and nasal polyps, has expanded the potential target indications for IL-13 inhibitors. Thirdly, advancements in biotechnology and the development of innovative monoclonal antibody therapies have improved the efficacy and safety profiles of IL-13 targeted treatments, boosting their adoption. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for IL-13s. These countries are increasingly adopting IL-13s due to their efficacy and potential to improve patient outcomes. On the other hand, the IL-13 market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the IL-13 market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
IL-13 drugs are used in the management of allergic asthma and atopic dermatitis, where it promotes airway hyperresponsiveness, mucus production and inflammation.
The Growth drivers of the IL-13 market include the increasing incidence and prevalence of allergic asthma and atopic dermatitis, advancements in biotechnology, and the development of innovative IL-13 inhibitors, expanding target indications.
The major players in this space are Arjil Pharma, GSK, Pfizer, Fortress, Novartis, Akesobio, Sanofi, Ionis, Menarini, Amgen, Roche, Cellabmed, J&J, Suzhou Maximum Bio-Tech, Astrazeneca, Shanghai Simnova Bio, Gilead.
One major restraint of the IL-13 market is the limited number of approved IL-13 targeted therapies, resulting in a lack of treatment options for patients. Additionally, the high cost of IL-13 targeted therapies may pose a financial burden for patients and healthcare systems, limiting access to these medications.
- Sanofi
- Arjil Pharma
- Gsk
- Pfizer
- Fortress
- Novartis
- Akesobio
- Sanofi
- Ionis
- Menarini
- Amgen
- Roche
- Cellabmed
- J&J
- Suzhou Maximum Bio-Tech
- Astrazeneca
- Shanghai Simnova Bio
- Gilead